US BANCORP \DE\ - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 193 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.4%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$104,000
+15.6%
6,214
-0.1%
0.00%
Q1 2020$90,000
-46.7%
6,222
+22.9%
0.00%
Q4 2019$169,000
+131.5%
5,064
+44.3%
0.00%
Q3 2019$73,000
+87.2%
3,510
+117.2%
0.00%
Q4 2018$39,000
-11.4%
1,6160.0%0.00%
Q3 2018$44,000
+2.3%
1,6160.0%0.00%
Q2 2018$43,000
-15.7%
1,6160.0%0.00%
Q1 2018$51,000
-16.4%
1,6160.0%0.00%
Q4 2017$61,0001,6160.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,100,146$117,248,00040.96%
TLP GROUP LLC 1,050,000$39,711,00027.53%
Aisling Capital LLC 2,240,000$84,717,00016.74%
Foresite Capital Management III, LLC 764,824$28,926,0008.12%
AlpInvest Partners B.V. 51,498$1,948,0006.95%
Vivo Capital, LLC 643,626$24,342,0005.21%
GREAT POINT PARTNERS LLC 573,550$21,692,0003.70%
Eventide Asset Management 1,226,000$46,367,0002.42%
Palo Alto Investors LP 1,146,419$43,358,0001.87%
HAMILTON LANE ADVISORS LLC 78,846$2,982,0001.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders